MedaCorp Specialist Robert Dreicer, MD, Deputy Director, UVA Cancer Center at the University of Virginia discusses Fusion Pharmaceuticals’ 225Ac-PSMA in prostate cancer on an Analyst/Industry conference call to be held on February 1 at 12 pm.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FUSN:
- Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
- Fusion Pharmaceuticals price target raised to $16 from $15 at Raymond James
- Fusion Pharmaceuticals price target raised to $15 from $13 at Oppenheimer
- Fusion Pharmaceuticals provides clinical and manufacturing updates
- RayzeBio downgraded to Hold from Buy at Truist